(B) Example of the gating strategy to determine p24+CD4+/mock- or P1095 LRVinfected primary CD4+T cells 72 hours after infection. cells. Keywords:AIDS/HIV Keywords:Immunoglobulins, Immunotherapy, NK cells == Introduction == Although antiretroviral therapy (ART) has been effective in controlling virus replication, Vanillylacetone delaying disease progression, and reducing HIV-1 transmission (1), it has had limited effects in preventing the seeding of the latent reservoir that persists during ART (2,3). The isolation of potent antiHIV-1 Envelope (Env) antibodies from natural infection has allowed the development of novel therapeutic agents in treatment of HIV-1 infection (46). Passive immunization with a single broadly neutralizing antibody (bNAb) (VRC01, 10-1074, or 3BNC117) has mediated suppression of viremia in HIV-1infected individuals (79), and only individuals with low plasma viral load demonstrated viral suppression to undetectable levels until systemic levels of antibody had decreased (9). In addition, passive immunization with VRC01 or 3BNC117 delayed viral rebound during analytical treatment interruption (10,11). Unfortunately, bNAb monotherapy did not prevent viral rebound either because of viral escape, indicating that bNAbs exerted selective pressure on the rebound virus (11), or because of outgrowth of preexisting resistant viral variants (810) and, as recently reported, did not demonstrate a decline in the size of viral reservoir (12). The outcomes of these studies have prompted in silico and computational predictions of the requirements for successful use of bNAbs in the field of HIV-1 prevention. These studies suggest that treatment with single antiHIV-1 monoclonal antibodies (mAbs) will lead to an emergence of viral resistance (13), and in vitro Rabbit Polyclonal to Pim-1 (phospho-Tyr309) testing supported this prediction (14). Moreover, Wagh et al. created a mathematical model and demonstrated in vitro that combinations of 3 or 4 4 mAbs increased neutralization potency and breadth and are more effective than any single mAb or combination of 2 mAbs (15). These results were supported by an independent in vitro neutralization study of 125 HIV-1 pseudotyped strains from various clades by a combination of 2, 3, and 4 mAbs for additive or synergistic effects, which demonstrated that an optimal combination of 3 or more bNAbs improved neutralizing breadth against HIV-1 viruses (16). Combinations of bNAbs have been administered to ART-naive humanized mouse and nonhuman primate preclinical models for treatment of established HIV-1 infection. Both animal models demonstrated that Vanillylacetone treatment with a combination of antibodies reduced viral load to undetectable levels, induced long-lasting immunity, and reduced Vanillylacetone measures of persistent viral infection; however, viral escape to at least one of the bNAbs in the combination was detected (1723). Human clinical trials treating antiretroviral-suppressed participants with combinations of 2 bNAbs have also demonstrated a delay in viral rebound upon analytical treatment interruption (2426). In both studies, more durable viral control was observed in individuals with viral sensitivity to all administered bNAbs. In these studies, the rebound virus either developed resistance to (25) or was linked to preexisting resistance to one of the bNAbs in the treatment combination but not to both bNAbs (24,26), indicating that an optimal combination may achieve acceptable therapeutic outcome. The effects of bNAbs can be mediated by both neutralization of virus and antibody-dependent cellular cytotoxicity (ADCC) through Fc receptormediated function, eliminating HIV-1infected cells. It is proposed that ADCC contributes to the kinetics of viral load reduction seen in vivo in elite controllers (27) and following bNAb administration (2833). ADCC, driven by bNAbs and non-neutralizing antibodies (non-NAbs), can Vanillylacetone also mediate killing of cells infected by the viruses that escaped neutralization and cells infected with neutralization-resistant viruses (34,35). Given the Vanillylacetone potential of mAbs in eradication of HIV-1 infection, we analyzed the potency and breadth of ADCC-mediating bNAb and non-NAb combinations against HIV-1infected cells. In order to recapitulate the effects of mAb combinations in vivo, we used an autologous in vitro system in which primary activated and infected CD4+T cells were used as targets and autologous purified natural killer (NK) cells were used as effectors. To ensure broad coverage of HIV-1 Env epitopes, we used 5 bNAbs that target nonoverlapping epitopes expressed on the viral Env spike as well as on the surface membrane of infected cells and 1 non-NAb that targets C1C2 epitope expressed on the Env upon engagement with the cell surface receptor CD4. To further.
